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ABSTRACT
Nonsense-mediated mRNA decay (NMD) is an mRNA
degradation pathway that regulates gene expres-
sion and mRNA quality. A complex network of
macromolecular interactions regulates NMD initia-
tion, which is only partially understood. According
to prevailing models, NMD begins by the assembly of
the SURF (SMG1–UPF1–eRF1–eRF3) complex at the
ribosome, followed by UPF1 activation by additional
factors such as UPF2 and UPF3. Elucidating the in-
teractions between NMD factors is essential to com-
prehend NMD, and here we demonstrate biochemi-
cally and structurally the interaction between human
UPF2 and eukaryotic release factor 3 (eRF3). In ad-
dition, we find that UPF2 associates with SURF and
ribosomes in cells, in an UPF3-independent manner.
Binding assays using a collection of UPF2 truncated
variants reveal that eRF3 binds to the C-terminal part
of UPF2. This region of UPF2 is partially coincident
with the UPF3-binding site as revealed by electron
microscopy of the UPF2–eRF3 complex. Accordingly,
we find that the interaction of UPF2 with UPF3b inter-
feres with the assembly of the UPF2–eRF3 complex,
and that UPF2 binds UPF3b more strongly than eRF3.
Together, our results highlight the role of UPF2 as a
platform for the transient interactions of several NMD
factors, including several components of SURF.
INTRODUCTION
Nonsense mediate mRNA decay (NMD) was originally de-
scribed as a quality control pathway whose function was to
identify mRNAs containing premature termination codons
(PTCs), which were then targeted for degradation (1–3).
SuchmRNAs could generate truncated proteins that can be
non-functional and/or affect normal cellular functions by
dominant-negative effects (4). NMD also plays a broader
role as one of several core cellular mechanisms that regu-
late gene expression of a significant number of physiological
mRNAs (5,6). Interestingly, recent evidence revealed that
NMD is important for stem cell differentiation by regulat-
ing the decay of mRNAs encoding factors essential for dif-
ferentiation and development of the embryo (7,8).
Deciding if an mRNA will be targeted for degradation
by the NMD pathway is defined during translation. Several
factors that bind to the translating ribosome and additional
cis- and trans-acting factors are required for NMD initia-
tion (3). These factors interact to assemble a complex set of
transient macromolecular complexes. Describing and char-
acterizing the interactions between all NMD factors, as well
as the similarities and differences between species, is essen-
tial to understand how an NMD response is triggered and
regulated. In mammals, three UPF (UP-Frameshift) pro-
teins conserved in eukaryotes, UPF1, an ATP-dependent
RNA helicase, UPF2 and UPF3, as well as the SMG1
(Suppressor with Morphogenetic effect on Genitalia 1) ki-
nase complex (SMG1C), consisting of SMG1, SMG8 and
SMG9, comprise the core NMD machinery (2,3). In mam-
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mals, UPF3 appears in two variants, UPF3a and UPF3b,
and we focus on UPF3b in this work (2).
A prevailing model suggests that UPF1 is recruited to
stalled ribosomes as part of the SURF (SMG1–UPF1-
eRF1–eRF3) complex, containing UPF1 helicase, SMG1
kinase and the eukaryotic release factors eRF1 (49 kDa)
and eRF3 (69 kDa) that control translation termination
in eukaryotes (3,9,10). UPF1 also binds mRNAs quite
promiscuously and independently of translation, whereas
translation has been shown to affect the distribution of
UPF1 on mRNAs (11–13). eRF1 and eRF3 form a com-
plex in the terminating ribosome, as revealed in the cry-
oEM structure of the mammalian eukaryotic release fac-
tor eRF1–eRF3-associated termination complex (14,15),
as well as in structural studies of the eRF1–eRF3 com-
plex (16). Crystal and EM structures of mammalian ribo-
somal complexes containing eRF1 have also been recently
described (17,18). In mammals, two distinct genes encode
for eRF3a and eRF3b, which have differences in their N-
terminal regions but both proteins can bind to eRF1 (19).
eRF3 comprises a GTP-binding domain (G-domain) and
two ß-barrel domains (domain 2/3) at the C-terminus (Fig-
ure 1A). Its GTPase activity is dependent on eRF1 and the
ribosome.
During NMD, the SURF complex in the ribosome as-
sociates with the exon junction complex (EJC), a complex
deposited 20–24 nt upstream of exon–exon junctions after
splicing, throughUPF2 andUPF3 (20–23). The interaction
of UPF2 to the CH domain of UPF1 stimulates its heli-
case activity, which is essential to trigger theNMD response
(20,21,23). The SMG1 kinase is responsible of UPF1 phos-
phorylation, an important event to recruit mRNA decay
machineries, and which is stimulated by UPF2 and UPF3b
(10,24,25). These macromolecular protein interactions are
regulated by additional factors such as the RUVBL1/2
complex (26) and the DHX34 helicase (27).
UPF2 is a 148 kDa protein comprising three conserved
MIF4G (middle domain of translation initiation factor
4G) domains (Figure 1A). The structure of MIF4G-1 and
MIF4G-2 has been determined by X-ray crystallography,
as well as the structure of the MIF4G-2 and MIF4G-3 do-
mains in tandem, which showed a perpendicular orienta-
tion between both domains (28). Also, electron microscopy
(EM) revealed the overall organization of full length UPF2
forming an open ring comprising the three MIF4G do-
mains (29–31). MIF4G-3 interacts with UPF3b (58 kDa)
as it is revealed in the crystal structure of MIF4G-3 bound
to the RRM (RNA-recognition motif) domain of UPF3b
(32) and in the EM structure of the UPF2–UPF3b complex
(29,30). UPF2 also interacts directly with SMG1, but the
function of this interaction remains unclear (28,31,33). Al-
thoughUPF2 is proposed to associate with SURFas part of
UPF3b–EJC complex, it can also form complex with UPF1
and SMG1 independently of UPF3b (10,31). Considering
that someNMDevents are independent ofUPF3b and EJC
(34–36), this opens the possibility that UPF2 could be di-
rectly recruited to SURF by multiple protein interactions
including UPF1, SMG1 and others.
Here, we have characterized the interaction between hu-
man UPF2 and eRF3. Yeast Upf2p and eRF3p interact in
vitro using purified proteins (37), but this interaction has
not been studied, up to our best knowledge, in mammals.
We demonstrate biochemically and structurally that eRF3
is a direct partner of UPF2 and that binding of UPF2 to
UPF3b interferes with the formation of the UPF2–eRF3
complex. eRF1–eRF3 is part of the SURF complex, assem-
bled during NMD initiation, suggesting that UPF2 could
be recruited to SURF and the ribosomes, which we cor-
roborate using pull down experiments and UPF2 mutants
with reduced affinity for UPF3. These results, together with
those of others, suggest that UPF2 has the potential to in-
teract with several NMD factors, including eRF3 at the ri-
bosome, UPF3b at the EJC, as well as UPF1 and SMG1.
It is unlikely that UPF2 can engage in all those interac-
tions simultaneously, and therefore, UPF2 possibly trans-
fers through several transient complexes, where it may con-
tribute to organize the order of events regulating NMD.
MATERIALS AND METHODS
Expression and purification of proteins in E. coli
UPF2 and UPF3b were produced as described in Melero
et al. (29). The RRM domain of UPF3b (residues 42–
143) and several fragments of UPF2 (UPF2761-1054 and
UPF2761-1227), were expressed and purified as described pre-
viously (22). Constructs UPF2121-486 and UPF2455-757 were
expressed in Escherichia coli BL21 (DE3) cells and purified
through its N-terminal His-tag following a similar protocol,
including the removal of the tag by TEV protease digestion.
eRF3a (CBP-eRF3a-His) and eRF1 (His-eRF1) were
expressed in BL21(DE3)pLysS cells grown in LB supple-
mented with 25 mg/ml kanamycin at 37◦C and expression
induced with 1 mM IPTG (final concentration) at 20◦C
overnight. Cells were lyzed in 70mMTris (pH 8.0), 300mM
KCl, 5% (v/v) glycerol, 1 mM PMSF, 0.1% (v/v) Triton X-
100 containing a cocktail of EDTA-free proteases inhibitors
(Roche). Lysate was cleared by centrifugation at 35 000 rpm
for 30 min at 4◦C, and the supernatant was applied to a
HisTrap HP column (GEHealthcare) equilibrated in buffer
containing 70 mM Tris (pH 8.0), 300 mM KCl, 5% (v/v)
glycerol and 40 mM imidazole. Elution was performed us-
ing a 40–500 mM imidazole gradient and fractions contain-
ing eRF1 or eRF3 were pooled and dialyzed overnight in
buffer Awithout imidazole for eRF1, or in buffer Awithout
imidazole but supplemented with 2 mM CaCl2 for eRF3a.
eRF3a was incubated with calmodulin affinity resin (Ag-
ilent Technologies) for 2 h at 4◦C on a rotating platform,
and eluted with 70 mM Tris pH 8.0, 300 mM KCl and 2
mM EGTA. Finally, proteins were applied to a Superdex
200 PC 3.2/30 column (GE Healthcare) equilibrated in 70
mM Tris (pH 8.0), 300 mM KCl, 5% (v/v) glycerol and 1
mM DTT. Purification of both proteins was monitored by
sodium dodecyl sulphate-polyacrylamide gel electrophore-
sis (SDS-PAGE) and SimplyBlue (Novex) staining.
Expression of proteins in human cells
The pEF Flag-HA-SBP-UPF1, pEF Flag-HA-SBP-
UPF2, pEFh SBP-UPF2, pEFh SBP-eGFP and
pEFh HA-SBP-MBP plasmids were previously defined
(31,38). UPF2 mutants expressing plasmids, pEFh SBP-
UPF2 164–765 (missing residues 1–163 and 766–1272),
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pEFh SBP-UPF2 2–1107 (missing residues 1107–1272),
pEFh SBP-UPF2 d904–1015 (missing residues 904–1015),
pEFh SBP-UPF2 d1016–1107 (missing residues 1016–
1107) and pEFh SBP-UPF2 d802–903 (missing residues
802–903) were generated by standard cloning procedures.
pSRD UPF1 (non-tagged, residues 1–1129) was generated
using restriction enzyme digestion protocol. pEFh SBP-
UPF3b and pEFh HA-SBP-UPF3b were generated from
codon optimized cDNA of human UPF3b (residues 2–483)
(Life Technologies). Mouse eRF3b (residues 2–632) was
polymerase chain reaction amplified from pFlag-CMV-




SBP-UPF2, SBP-UPF3b, SBP-eRF3b, SBP-eGFP and
SBP-MBP were purified as described before (40). In brief,
293T cells were co-transfected with plasmids listed above
using polyethyleneimine (Polysciences). After transfection,
cells were lysed in NF-lysis buffer [20mM Tris (pH 7.5),
150 mM NaCl, 0.25 M Sucrose, 0.5% (v/v) NP-40, 1%
(v/v) Tween 20] containing 1 mM DTT, protease inhibitor
cocktail (Nacalai Tesque), phosphatase inhibitor cocktail
(EDTA free) (Nacalai Tesque) and 50 g/ml RNase A.
SBP-tagged proteins were captured by Streptavidin Mag
Sepharose (GE Healthcare) and eluted with T buffer (20
mM HEPES (pH 7.5), 150 mM NaCl, 2.5 mM MgCl2,
0.05% (v/v) Tween 20) containing 1 mM DTT, protease
inhibitor cocktail (EDTA free) (Nacalai Tesque), phos-
phatase inhibitor cocktail (Nacalai Tesque) and 2 mM
biotin (Sigma-Aldrich). All SBP-UPF2 versions generated
for this work was produced and purified using an identical
protocol as that described above.
Interaction assays by size exclusion chromatography (SEC)
Purified proteins and complexes were pre-incubated at 30◦C
for 30 min with agitation and subsequently loaded on a Su-
perdex 200 PC 3.2/30 column (GEHealthcare) equilibrated
with 20 mM Tris (pH 7.4), 150 mM NaCl, 1 mM DTT,
1 mM MgCl2 and 5% (v/v) glycerol. For the experiments
described in Figure 1, UPF2 (5.7 g) was either incubated
withUPF3b (6g), eRF1 (5g) (1:2.65UPF2/UPF3bmo-
lar ratio) or eRF3a (4g) (1:1.5 UPF2/eRF3amolar ratio),
in 50 l reaction and the mixtures were fractionated by size
exclusion chromatography (SEC). Fractions containing the
proteins were analyzed by SDS-PAGE and Oriole Fluores-
cent Gel Stain (Bio-Rad).
In vitro pull down experiments
For in vitro protein-binding assays, 3 × 107 of 293T cell ex-
tracts transfected with pEFs HA-SBP-eRF3b, pEFs HA-
SBP-UPF3b or pEFs HA-SBP-MBP plasmids were lysed
in NF buffer containing 50 g/ml RNase A and incubated
with 0.5mg of anti-HA-tagmAb-Magnetic beads (TANA2,
MBL) for 2 h at 4◦C. The beads were washed with T buffer
and separated into 5–6 tubes. The separated beads were in-
cubated with 200 nM of SBP-UPF2 wild-type (wt) or its
derivatives (experiments in Figure 3), or 200 nM of SBP-
UPF2 pre-incubated with 200 or 400 nM SBP-UPF3b (ex-
periments in Figure 4) for 30 min in T buffer supplemented
with 1 mMMgCl2, 1 mMMnCl2, 1 MZnCl2, 1 mMDTT
and 0.0025% (w/v) BSA. In Figure 2, 600 nMSBP-eGFP or
SBP-eRF3b were mixed with 200 nM of the indicated Flag-
HA-SBP-tagged proteins for 1 h. Then, mixtures were in-
cubated with 0.5 mg of anti-HA-tag mAb-Magnetic beads.
In Figure 6, 30 nM Flag-HA-SMG1C and 90 nM HA-
UPF1/SBP-UPF2 complex were pre-assembled and immo-
bilized with Flag-M2-Mag-beads (Sigma-Aldrich). Then,
increasing amounts of UPF3b (9, 30 and 90 nM) were
added. After 2 h of incubation, the beads were washed two
times with T buffer containing 1 mMDTT. The bound pro-
teins were eluted with SDS sample buffer lacking reducing
agents. After addition of reducing agents and heat denat-
uration, the eluted proteins were separated by SDS-PAGE
and stained using Oriole Fluorescent Gel Stain (Bio-Rad).
Experiments were performed three times, and typical results
are shown.
Immunoprecipitation of HA-tagged-UPF2 from HeLa
TetOff cells and western blot analysis
The pSR HA-UPF2, pSR HA-UPF2-E858R and
pSR HA-UPF2-dU3 plasmids were previously defined
(10). For immunoprecipitation, HeLa TetOff cells were
transfected with the indicated plasmids using Lipofec-
tamine LTX (Invitrogen). Two days after transfection, cells
were lysed with a loose-fit Potter-ElvehjemHomogenizer in
T-buffer with 50 g/ml RNase A. Lysates were incubated
with 1.5 g of anti-HA rat monoclonal antibody (3F10,
Roche) at 4◦C for 1 h, mixed with 2 mg of protein-G-
Dynabeads (Life technologies) and incubated at 4◦C for
40 min. After washing with RNase(-) T-lysis buffer, the
beads were eluted with SDS sample buffer containing 50
mM DTT. Eluted proteins were separated by SDS-PAGE
and analyzed by western blot with the indicated antibodies.
Experiments were performed three times, and typical
results are shown.
Interaction assays using bio-layer interferometry (BLI)
The interaction between UPF2, either full-length or several
fragments, with eRF3a, eRF3b and UPF3b was analyzed
using a single channel BLItz system with Ni-NTA biosen-
sors (ForteBio, Menlo Park, CA, USA). His-tagged ligand
proteins, either UPF2, eRF3a or UPF3b, were immobilized
through their His-tag on the sensors, at a final concentra-
tion of 6.75, 4 and 20 M respectively in 70 mM Tris (pH
8.0), 300 mMKCl, 15% (v/v) glycerol and 1 mMDTT. Bio-
layer interferometry (BLI) experiments were performed at
ambient temperature and shake speed of 2200 rpm, with
baseline for 30 s followed by an association phase (exper-
imental sample) for 300 s and a dissociation phase (buffer
alone) for 300 s. The interacting proteins in analyte solu-
tions were added at several concentrations to generate the
sensorgrams and estimate the affinity constant (KD), using
the BLItz Pro software in a global manner using a simple
1:1 binding model. This software allowed a global analysis
to determine a single pair of rate constants (Ka, Kd) for net
binding and dissociation, the equilibrium dissociation con-
stant (KD = Kd/Ka), as well as the goodness of fit (R2). A
control experiment using just buffer as analyte served as a
blank for correction of sensorgrams.
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Antibodies
Antibodies against SMG1, UPF1, UPF2, UPF3b and
eIF4A3 were described previously (9,10,41). Antibodies
against Flag (M2, Sigma), SBP (SB19-C4, SantaCruz),
MLN51 (Sigma), Y14 (Abcam), Magoh (Abcam), rpS6
(Cell signalling technology), rpL7a (Cell signalling technol-
ogy) and MBP (NEB) were obtained commercially. HeLa
cell nuclear extracts were purchased from CILBiotech (Bel-
gium).
EM and 3D reconstruction
Electron microscopy of UPF2-eRF3 was performed using
a JEOL-1230 Transmission Electron Microscope operated
at 100 kV after the samples were stained using 1% uranyl
formate. Images of single molecules were recorded auto-
matically at a final magnification of 2.28 A˚ per pixel us-
ing the F416 CMOS camera from TVIPS under the con-
trol of the EM-TOOLs program. A total of 143366 images
were automatically extracted from the micrographs and se-
lected bad particles (noise and background) were identi-
fied and removed by 2D classification using RELION (42),
ending with a dataset containing 73057 images (Supple-
mentary Figure S1). After a new round of 2D classifica-
tion, we detected a number of images corresponding to
UPF2 by comparing with images of purified UPF2. The
remaining data set was then refined, assuming that con-
tained mostly images corresponding to UPF2–eRF3. Sev-
eral methods were used to generate a collection of initial
templates for refinement, a phantom blob with the approxi-
mate size of the UPF2–eRF3 complex, a low pass filter ver-
sion of UPF2 (29), and a volume generated using reference-
free averages of the complex and EMAN2 initial volume
generator (command: e2initialmodel.py)(43) (Supplemen-
tary Figure S2). When starting refinement from a low pass
filter version of UPF2 or a blob, first rounds of refine-
ment used reference-free averages as input, since these have
a better signal to noise ration, better suited to initiate re-
finement from references without much features. After sev-
eral rounds, refinement was followed using single particles.
Volumes converged to similar low-resolution solutions af-
ter some rounds of refinement, despite the bias introduced
by the initial reference. Then, the preliminary model of
UPF2–eRF3 obtained using EMAN2 initial volume gen-
erator (command: e2initialmodel.py)(43) was used as seed
to search in 3D for images of free UPF2 using maximum-
likelihood methods in RELION (42). After this 3D classi-
fication, 19053 images of UPF2 were found to still be part
of the dataset (Supplementary Figure S1). These were re-
moved and the remaining 54004 images of the UPF2–eRF3
complex were refined until convergence using EMAN (44)
and the initial template obtain from the EMAN2 initial
volume generator. After refinement, the images processed
showed a good distribution of Euler angles (Supplementary
Figure S3). The resolution of the structure was estimated
as 20.0 A˚, using the Fourier Shell Correlation method and
a 0.5 correlation coefficient (Supplementary Figure S3).
Atomic structures of MIF4G domain 1 (MIF4G-1) and
the tandem MIF4G2–3 of UPF2 (28), and the model of
eRF3a (residues 207–634) (14) were fitted within the EM
structure of UPF2–eRF3 using UCSF Chimera (45) (cross-
correlation = 0.9461, 0.8833 and 0.8124, respectively). We
were unable to define the handedness of the final structure.
One hand was used for representation, but the opposite
hand cannot be discarded.
Whole cell extract preparation, in vitro splicing and immuno-
precipitation
HEK293T cells were transfected with Flag-pcDNA3 vec-
tor, Flag-UPF1, Flag-UPF2 or Flag-UPF3b plasmid (10).
After 48 h incubation, transfected cells were harvested and
whole cell extracts were prepared as previously described
(46,47). Briefly, the transfected cells were harvested by
pipetting and collected by low-speed centrifugation at∼500
× g for 5 min, at 4◦C. The resulting pellet was washed with
ice-cold phosphate bufferedsaline (PBS) and re-suspended
in ice-cold buffer E (20 mM HEPES-KOH (pH 7.9), 100
mMKCl, 0.2 mMEDTA, 10% (v/v) glycerol, 1 mMDTT).
Typically, 200 l of buffer E was used per 10 cm plate. Dis-
rupt cells by sonication with anUltrasonic processorModel
ULTRA S. Homogenizer VP-5s (TAITEC, Japan). Sonica-
tion is carried out at 30% continuous for 5 s three times and
30 s incubation on ice between bursts. The sonicated lysate
was centrifuged at 15 000 × g, 20 min at 4◦C. The super-
natant was saved as the whole cell extract. The substrates
for in vitro splicing reaction were prepared as described pre-
viously. The in vitro splicing reactions in combination with
HEK293T cell extracts were carried out essentially as re-
ported previously (46,47). Briefly, a typical 50 l splicing
reaction with 2 × 105 cpm of 32P-labeled transcripts con-
tains 10 l of HeLa cell nuclear extract (CILBIOTECH,
Belgium) and 20 l of HEK293T cell whole cell extract as
well as 5 l of 10 × SP buffer. Following 1 h incubation
at 30◦C, reaction mixture was diluted five times with RNA
IP buffer [20 mMHEPES-NaOH (pH 8.0), 150 mMNaCl,
0.05% (v/v) Triton X-100] and immunoprecipitation with
anti-Flag (M2, Sigma) antibody was performed using 200
l of the mixture and 20 l of M2 resin as described previ-
ously (46,47).
Polysome analysis
For polysome profile analysis, 2 × 107 of HeLa cell were
washed with ice-cold PBS containing 50 g/ml cyclohex-
imide and harvested. Harvested cells were resuspended in 2
ml of cold reticulocyte standard buffer (RSB) [10 mM Tris
(pH 7.5), 10 mM NaCl, 1.5 mM MgCl2, 50 g/ml cyclo-
heximide, 2 g/ml aprotinin, 2 mM PMSF]. Cell suspen-
sions were separated in two tubes, and an equal volume of
RBS buffer containing 1% (v/v) Triton X-100, 1% (v/v)
deoxycholate, 2% (v/v) Tween 20 with or without 50 mM
EDTA was added. The suspensions were Dounce homog-
enized and centrifuged for 30 min at 13 000 × g. A total
of 1 ml of supernatant was loaded onto a linear gradient
of 8 to 45% (w/v) sucrose in sucrose gradient buffer [10
mM Tris (pH 7.5), 75 mM KCl, 3 mM MgCl2] and cen-
trifuge in a SW40 rotor for 3 h at 36 000 rpm and 4◦C. The
gradient was collected from the bottom of the tube at 0.6
ml/min/tube. The A254/UV was monitored with A254 fil-
ter set. To concentrate each fraction, sodium-deoxycholate
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and trichloroacetic acid were added to final concentrations
of 4 and 24% (v/v), respectively, and centrifuge 10 min at 13
000 × g. Precipitates were rinsed with 80% (v/v) acetone at
−20◦C and suspended by 1× SDS sample buffer containing
5% (v/v) -ME. Fractions were separated by SDS-PAGE,
and analyzed by western blot with the indicated antibodies.
Experiments were performed twice, and typical results are
shown.
RESULTS
Direct interaction between human UPF2 and eRF3
UPF2, eRF1 and eRF3 (eRF3a, one of the variants of
eRF3; eRF3 from now on, unless specified) were expressed
in E. coli and purified to homogeneity (Figure 1B). eRF3
and eRF1 were produced as tagged proteins, CBP-eRF3-
His and His-eRF1 (named eRF3 and eRF1 through this
manuscript, for simplicity). We analyzed if UPF2 could
form a direct complex with eRF3 or eRF1 after incubat-
ing and resolving the proteins by SEC using a Superdex
200 PC 3.2/30 column (GE-Healthcare). Control experi-
ments defined the elution profile for each of the individ-
ual proteins (Figure 1C). Then, UPF2 was either incubated
with eRF3 or eRF1, and the mixture was fractionated us-
ing SEC. When UPF2 and eRF1 were mixed (1:2.65 mo-
lar ratio), the elution profile revealed two peaks, with sim-
ilar elution times to those obtained for UPF2 (elution at
1.3 ml), and eRF1 (elution at 1.7 ml) injected individu-
ally and co-migration was not found when the fractions
were analyzed by SDS-PAGE. Thus, UPF2 and eRF1 were
not interacting under our experimental conditions (Figure
1D). On the other hand, when UPF2 and eRF3 were mixed
(1:1.5 molar ratio), one peak eluted earlier than UPF2 in-
jected alone (elution at 1.3 ml compared to 1.37 ml for
UPF2 alone), and a significant shift in the elution profile of
eRF3 was observed by SDS-PAGE of the fractions (Figure
1E). These observations suggested that UPF2 was forming
a complex with eRF3 under our experimental conditions,
whereas UPF2 did not interact with eRF1.
To further support that UPF2 and eRF3 can form a com-
plex, we performed several pull down experiments using
proteins expressed in human cells (Figure 2A). For this, HA
(hemagglutinin) and SBP (Streptavidin Binding Peptide)
tagged versions of UPF2 (Flag-HA-SBP-UPF2) and UPF1
(Flag-HA-SBP-UPF1) were produced in HEK 293T cells
and enriched after affinity purification. We also produced
UPF2 partially bound to UPF1 by co-expressing Flag-HA-
SBP-UPF2 and untagged UPF1, following a similar strat-
egy we used before (31). This time, our preparation showed
only partial occupancy of UPF2, but all UPF1 co-purifying
with UPF2 must be forming a complex with UPF2, since
UPF1 was not tagged (Figure 2A; note that UPF1 and
HA-SBP-UPF1 run differently in SDS-PAGE). The inter-
action between these proteins and eRF3 was studied by pull
down through theHA tag using immobilizedmagnet beads.
eRF3a aggregated when expressed in these cells, and thus
we worked with eRF3b, produced as SBP-eRF3b (the use
of eRF3b will be specified from now on; otherwise eRF3
stands for eRF3a), which did not aggregate (Figure 2A).
All Flag-HA-SBP-tagged proteins did not precipitate SBP-
eGFP (Figure 2B, lane 1–4, and 9–12, SBP-eGFP high-
lighted within a square). In addition, SBP-eRF3b did not
interact with Flag-HA-SBP-tagged MBP (Figure 2B, lanes
5 and 13), ruling out that the interactions detected could
be an artifact. We found that SBP-eRF3b interacted with
UPF1 (Figure 2B, lane 6 and 14, pull down Flag-HA-SBP-
UPF1 labeled with #, and co-precipitated eRF3b indicated
within a square), as previously described (24), but also with
UPF2 (Figure 2B, lane 7 and 15, co-precipitated eRF3b
labeled within a square). The UPF2–UPF1 complex also
interacted with eRF3b, indicating that the interaction of
UPF1 and UPF2 is compatible with the binding to eRF3b
(Figure 2B, lane 8 and 16).
UPF2 interacts with eRF3 less strongly than with UPF3
We measured the affinity constant for the interaction be-
tween UPF2 and eRF3 using BLI. A layer of eRF3a was
immobilized on a biosensor tip using the His tag, and sev-
eral concentrations of UPF2were used to calculate an affin-
ity constant (KD) of 2.18 ± 0.5 M (Figure 2C, Table 1).
Values were also calculated for the eRF3b isoform puri-
fied from human cells, but this time, a His-tagged version
of UPF2 was immobilized on the biosensor tip and SBP-
eRF3b was used (KD = 6.27 ± 3.05 M; Table 1). We also
calculated the KD for the interaction between UPF2 and
UPF3b using a similar experimental set up (Table 1). The
values for theUPF2-UPF3b affinity constant obtained here
(KD = 0.02 ± 0.01 M) (Figure 2D, Table 1) were in the
same range as those described before using Surface Plas-
mon Resonance (22). Interestingly, the interaction between
UPF2 and UPF3b was significantly stronger than between
UPF2 and eRF3.
eRF3 binds to the C-terminal region of UPF2
A series of SBP-tagged UPF2 constructs and mutants and
HA-SBP-eRF3b were used to narrow down what region in
UPF2 is involved in contacting eRF3b in pull down exper-
iments (Figure 3A and Bi). UPF2 (164–765), a large frag-
ment of UPF2 comprisingMIF4G-1 andMIF4G-2 did not
show a significant interaction with eRF3b when compared
with wt UPF2, suggesting that the UPF2–eRF3b interac-
tion surface is mostly placed at the C-terminus of UPF2
(Figure 3C, lane 2 and 9; note that UPF2 (164–765) runs
faster in the SDS-PAGE). In agreement with this, the UPF2
(1016–1107) truncation reduced binding to eRF3b signif-
icantly compared to wt UPF2 (Figure 3C, lanes 5 and 12),
confirming that UPF2–eRF3 interaction surface is placed
at theUPF2C-terminal region. Together, these experiments
indicated that the C-terminal end of UPF2, around the
MIF4G-3 domain, defines an important region to maintain
the interaction between UPF2 and eRF3b. This would be
compatible with the interacting surface between UPF2 and
eRF3b involving a larger region around domain MIF4G-3
and the C-terminus of UPF2.
These results were further confirmed using four frag-
ments of UPF2, expressed and purified from E. coli,
UPF2121-486, UPF2455-757, UPF2761-1054 and UPF2761-1227,
and corresponding approximately to domain MIF4G-1,
MIF4G-2, MIF4G-3 and MIF4G-3 plus regions at the C-
terminus of this domain (Figure 3Bii). The interaction be-
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Figure 1. UPF2 interacts with eRF3 in vitro. (A) Schematic representation of the sequence and domain arrangement in human UPF2 and eRF3a. Regions
obtained from known crystal structures or homology models (in case of MIF4G-1 and MIF4G-2 in UPF2) are indicated. The MIF4G domains of UPF2
are colored in blue, and the G-domain and the ß-barrel domain of eRF3a are in orange. (B) Sodium dodecyl sulphate-polyacrylamide gel electrophoresis
(SDS-PAGE) and SimplyBlue (Novex) staining of purified UPF2, eRF3 and eRF1 used in these studies. Molecular Weight markers are indicated (kDa).
(C) Size exclusion chromatography (SEC) of purified UPF2, eRF3a and eRF1. Elution volumes are indicated on top of the peaks (in ml). Bottom panels
show SDS-PAGE and SimplyBlue (Novex) staining of the fractions containing the peaks in each case. (D and E) SEC experiments to analyze the potential
interaction of UPF2 with eRF1 (D) and with eRF3a (E). A mixture of UPF2 and either protein was loaded onto the column and fractionated as in (C).
Bottom panels show SDS-PAGE and SimplyBlue (Novex) staining of the fractions containing the peaks in each experiment, and below these, the fractions
corresponding to the proteins analyzed individually under similar conditions, to help the comparison. UPF2 co-migrated with eRF3 in high molecular
weight fractions (highlighted within a red square) compared to the control runs.
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Figure 2. UPF2 interacts with eRF3. (A) SDS-PAGE and Oriole Fluorescent Gel Stain (Bio-Rad) staining of purified HA-SBP-tagged and SBP-tagged
proteins used for the interaction assays. (B) HA-pull down experiments to test the interaction of Flag-HA-SBP-UPF1 and Flag-HA-SBP-UPF2 with SBP-
eRF3b. Controls using Flag-HA-SBP-MBP and SBP-eGFP were used to discard artifacts. Input and pull down material were analyzed by SDS-PAGE
and Oriole Fluorescent Gel Stain (Bio-Rad). For clarity, eRF3b and SBP-eGFP in the input and co-precipitated material are highlighted within a square.
HA-SBP-UPF1 (#) and non-taggedUPF1 (*) are also indicated. Non-taggedUPF1 in the HA-SBP-UPF2:UPF1 complex decreased in both eGFP control
pull down (lane 4) and eRF3b pull down (lane 8), suggesting that some UPF1 in the complex is washed out during experiment. BSA in the input material
is indicated. LC indicates the positions of IgG light chain. (C) Sensorgrams from bio-layer interferometry (BLI) experiments performed to estimate the
affinity constants for eRF3a-UPF2 complex. eRF3a was immobilized to the tip of the sensor through its His-tag (ligand) and increasing concentrations of
UPF2 (analyte) were tested for interaction. (D) Sensorgrams as in (C), but for the interaction between UPF3b (ligand) and UPF2 (analyte).
tween UPF2 fragments and eRF3 was analyzed by BLI, re-
vealing that only the C-terminal fragments of UPF2 inter-
acted significantly with eRF3. Interestingly, the sameUPF2
constructs that interacted with eRF3 were also found to be
capable of binding to UPF3b (Figure 3D, Table 1).
Taken together, these results clearly show that UPF2 and
eRF3 interact, and that the region of interaction involves
the C-terminal end of UPF2, around the third MIF4G do-
main, which is at least partially coincident with the regions
involved in UPF3b binding.
3D structure of the UPF2–RF3 complex
The UPF2–eRF3 complex was then reconstituted by mix-
ing UPF2 and eRF3. The complex was resolved by SEC,
and the peak fraction corresponding to elution volume 1.3
ml and containing both proteins (Figure 1E) was observed
in the electron microscope after staining with 1% (w/v)
uranyl formate to help visualizing the complex. The molec-
ular weight and dimensions of theUPF2–eRF3 complex are
relatively small to be easily visualized and resolved by cryo-
EM of vitrified samples, where the signal of the complex
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Figure 3. eRF3 binds the C-terminal region of UPF2. (A) Schematic representation of several SBP-tagged versions of UPF2 used for the interaction
assays. (B) (i) SDS-PAGE and Oriole Fluorescent Gel Stain (Bio-Rad) staining of purified SBP-tagged versions of UPF2 used for the interaction assays
(left panel), and 20% ofHA-SBP-eRF3b bound to anti-HAmagnetic beads and eluted with SDS sample buffer (right panel).MolecularWeight markers are
indicated (kDa). (ii) SDS-PAGE and SimplyBlue (Novex) staining of purified fragments of UPF2 produced in Escherichia coli (UPF2121-486, UPF2455-757,
UPF2761-1054 and UPF2761-1227, corresponding approximately to domain MIF4G-1, MIF4G-2, MIF4G-3 and MIF4G-3 plus regions at the C-terminus).
Molecular Weight markers are indicated (kDa). (C) HA-pulldown experiments to test the interaction of the SBP-tagged versions of UPF2 shown in (A)
and HA-SBP-eRF3b. HA-SBP-eRF3b immobilized on anti-HA magnetic beads were incubated with SBP-eGFP (as control, lanes 4 and 14), SBP-UPF2
wild-type (wt) (lanes 1 and 8) or its derivatives (400 nM each) (lanes 2–6 and 9–13). A total of 50% of input and 50% of precipitatedmaterials were subjected
to SDS-PAGE and stained with Oriole Fluorescent Gel Stain (Bio-Rad). Asterisk (*), BSA and LC indicate the positions of UPF2 wt and its derivatives,
BSA and IgG light chain, respectively. Note that SBP-UPF2 (164–765) runs faster than the rest of UPF2 mutants. The region within a square is shown
below in a darker exposure to highlight the presence of UPF2 mutants. SBP-UPF2 (164–765) does not appear here as it is run in a different position in
the gel. Molecular Weight markers are indicated (kDa). (D) Sensorgrams from BLI experiments to test the interaction between eRF3a (upper panel) or
UPF3b (bottom panel) to the indicated constructs of UPF2 (UPF2121-486, UPF2455-757, UPF2761-1054 and UPF2761-1227) at a final concentration of 8 M.
Experiments were performed three times for the calculation of kinetic parameters and a typical sensorgram for each condition is shown.
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Table 1. Kinetic parameters measured by BLI for the interaction of eRF3a, eRF3b and UPF3b with UPF2 and several constructs of UPF2
Ligand Analyte KD (M) ka (M−1·s−1) kd (s−1) R2
eRF3a UPF2 WT 2.18 ± 0.51·10−6 3.24·102 6.89·10−4 0.98
UPF2121-486 2.69 ± 3.77·10−2 2.31·101 1.49·10−2 0.95
UPF2455-757 1.32 ± 0.30·10−4 9.34·101 1.17·10−2 0.93
UPF2761-1054 3.66 ± 0.44·10−5 9.19·101 3.34·10−3 0.95
UPF2761-1227 1.64 ± 0.66·10−5 1.91·102 2.95·10−3 0.95
UPF3b WT 1.12 ± 1.11·10−5 6.24·103 4.54·10−2 0.98
UPF3b42–143 5.18 ± 2.41·10−5 1.30·102 5.99·10−3 0.92
UPF3b UPF2 WT 2.07 ± 1.59·10−8 4.18·104 5.83·10−4 0.98
UPF2121-486 2.74 ± 0.31·10−5 4.77·102 1.32·10−2 0.95
UPF2455-757 2.49 ± 1.18·10−5 1.85·103 4.02·10−2 0.98
UPF2761-1054 3.69 ± 0.98·10−8 6.87·104 2.51·10−3 0.96
UPF2761-1227 3.99 ± 0.43·10−8 4.99·104 1.99·10−3 0.95
UPF2 eRF3b 6.27 ± 3.05·10−6 1.34·104 4.20·10−2 0.95
Affinity constant (KD), rate constants (ka, kd) and the goodness of fit (R2) values are the average of at least three independent experiments, using several
concentrations for each BLI interaction assay.
has to be sufficiently good to detect and align the images
during image processing. Larger complexes, such as ribo-
somes, are better targets for these single-molecule methods.
Although there are a number of successful cases for small
proteins, these experiments are still very challenging. Thus,
we used a staining agent to increase the signal of the images
and facilitate determining the 3D structure although at low
resolution (Figure 4A).
Images of single molecules were extracted and these were
computationally processed and classified (see ‘Materials
andMethods’ section for details and Supplementary Figure
S1). After classification, we found that a subset of images
were identical to those obtained for UPF2 alone (29,30),
whereas other molecule images were larger, as expected for
the UPF2–eRF3 complex (Figure 4B). Averages of UPF2
revealed a round shape compatible with the open ring struc-
ture described for this protein (29,30) (Figure 4C). Inter-
estingly, the averages for UPF2–eRF3 also showed a round
region, but some additional density was attached (Figure
4C). This was interpreted as resulting from the interaction
between UPF2 and eRF3.
A 2D and 3D classification strategy was designed to iso-
late the images of UPF2–eRF3 and remove those of free
UPF2 still present in the peak of the SEC (Supplementary
Figure S1). A total of 54004 images of UPF2–eRF3 were
identified following this procedure and these were refined
using angular refinement methods. To discard any bias dur-
ing image processing, we used several templates as models
to start image refinement, including models obtained with-
out any information from previous structures and we also
used only the images of the UPF2–eRF3 complex obtained
here (Supplementary Figure S2).
The structure of UPF2–eRF3 solved at 20 A˚ resolution
revealed a flat open ring with an additional density pro-
truding (Figure 4D, Supplementary Figure S3). The open
ring region was reminiscent of the ring structure defined
for UPF2 before (29,30). To locate the position of UPF2
and eRF3 within the complex, we aligned the structures
of UPF2 (29) and UPF2–eRF3 and we calculated a differ-
ence map that helped us to segment the structure. This sub-
traction identified two distinct regions within UPF2–eRF3,
one matching UPF2 (Figure 4D, blue color), whereas the
remaining density could then be assigned to eRF3 (Fig-
ure 4D, orange color). To estimate the mass occupied by
each protein within the complex, we calculated the molecu-
lar mass of each segmented map individually using the vol-
ume command implemented in EMAN (44). This algorithm
estimates the volume enclosed by the EM map, at a given
threshold of visualization, assuming a protein density aver-
age of 1.35 g/ml (0.81 Da/A3). By doing this, we estimated
a mass of 168 kDa for the UPF2 region, and 72 kDa for
eRF3, which correlated well with their predicted molecular
weights (148 and 79 kDa, respectively).
At this resolution, UPF2 appeared segmented in three
main regions of density that could correspond to the three
MIF4G domains. One end of the UPF2 ring was bound to
eRF3, which should correspond to the C-terminal half of
UPF2, as we had determined biochemically (Figure 3D).
The crystal structure of the MIF4G domains 2 and 3 in
tandem form a rigid assembly where the two domains are
placed orthogonally respect to each other (28) and this
structure could be fitted within the end of the UPF2 ring
bound to eRF3 (cross-correlation = 0.88) (Figure 4E).
Crystal structures of fragments of Schizosaccharomyces
pombe eRF3 (residues 196–662; PDB ID: 1R5B) (48), and
human eRF3 (residues 439–637; PDB ID: 3E1Y) (16) have
been solved. The structure of eRF3 has also been deter-
mined at lower resolutions, as part of an eRF1/eRF3/GTP
complex using SAXS (16), and as part of a complex with
the ribosome (14,15). The cryoEM of the ribosomal pre-
termination complex associated with eRF1/eRF3 at a res-
olution of 9.7 A˚, enabled to propose an atomic model of
the eRF1–eRF3 complex using the available crystal struc-
tures and constrains introduced by the cryoEM structure
(PDB ID: 3J5Y) (14). Residues 207–634 of eRF3weremod-
eled and the comparison between this model and the den-
sity assigned to eRF3 in the UPF2–eRF3 complex showed
that the EM map had overall dimensions consistent with
size of eRF3 (Figure 4E). Some density was still available in
the EM map to account for the N-terminal region of eRF3
missing in the atomic model. Nonetheless, it is important
to stress that the intention of this comparison was only to
determine if the range of dimensions in the EM map were
consistent with eRF3, since the resolution was insufficient
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Figure 4. Electron microscopy of the UPF2–eRF3 complex. (A) Representative micrograph of the negative stained UPF2–eRF3a complex using the
electron microscope. Scale bar represents 50 nm. (B) Images of single molecules obtained for the UPF2–eRF3a complex using EM. Right panels show
some selected 2D reference-free averages obtained after alignment and averaging those images corresponding to views of the UPF2–eRF3a complex in
similar orientation. Scale bar represents 10 nm. (C) Representative 2D averages for UPF2 and UPF2–eRF3a. Scale bar represents 10 nm. (D) 3D structure
of UPF2–eRF3a where UPF2 and eRF3a components have been segmented and color differently (UPF2, blue color; eRF3a, orange color). Segmentation
of the UPF2–eRF3a complex was performed using UCSF Chimera (45). Two views of the complex are shown. Scale bar represents 2 nm. (E) Fitting of
atomic structures into the UPF2–eRF3a EM map. The 3D structure of UPF2–eRF3a is shown as a white transparent density with the crystal structures
of UPF2 domains (28) and a model of eRF3 fitted. The eRF3 model corresponds to a fragment of eRF3 (residues 207–634) (PDB 3J5Y) (14,15). Scale bar
represents 2 nm.
to define a precise orientation of eRF3 within the UPF2–
eRF3 complex.
The interaction of UPF2 with UPF3b affects binding to eRF3
The structure ofUPF2–eRF3 revealed some interesting fea-
tures of this complex. First, eRF3 interacted preferentially
with one of the two sides of the UPF2 open ring. Second,
eRF3 occupied an area in UPF2 that could potentially par-
tially overlap with the regions in UPF2 that bind to UPF3b
(29). This was also suggestedwhen analyzing the interaction
of C-terminal fragments of UPF2 with eRF3 and UPF3b
(Figure 3). Nonetheless, at 20 A˚ resolution (this study and
Melero et al. (29)), it was not possibly to completely define
if the side of the UPF2 ring involved in eRF3 binding is the
same as the one proposed before to bind UPF3b (29).
Thus, we decide to analyze if UPF3b could interfere
with binding of eRF3 to UPF2, using SBP-UPF2 and
SBP-UPF3b purified from cells (Figure 5A), and HA-SBP-
eRF3b, HA-SBP-UPF3b and HA-SBP-MBP that could be
precipitated using the HA-magnetic beads (Figure 5B). As
controls, we confirmed that HA-SBP-UPF3b (Figure 5C,
labeled #) and HA-SBP-eRF3b could bind to SBP-UPF2,
whereasHA-SBP-MBPdid not precipitate SBP-UPF2, sug-
gesting this experimental set up was not producing artifacts
(Figure 5C). Note that the amount of UPF2 co-precipitated
with eRF3b is much smaller than that of UPF3, in agree-
ment with the KD values obtained in BLI experiments. In-
terestingly, whereasHA-SBP-eRF3b could precipitate SBP-
UPF2 (Figure 5C, lane 4 and 8, within a square), pre-
incubation of SBP-UPF2 with SBP-UPF3b significantly re-
duced the interaction of SBP-UPF2 with HA-SBP-eRF3b
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Figure 5. UPF3b binding to UPF2 affects recruitment of eRF3 to UPF2. (A) SDS-PAGE and Oriole Fluorescent Gel Stain (Bio-Rad) staining of purified
SBP-UPF2 and SBP-UPF3b to be used in competition experiments in (C). (B) Purified HA-SBP-UPF3, HA-SBP-MBP and HA-BP-eRF3b were immo-
bilized using magnetic beads. SDS-PAGE stained with Oriole Fluorescent Gel Stain (Bio-Rad) is shown. (C) Competition between UPF3b and eRF3b
to bind UPF2 tested by HA-tag pulldown. HA-SBP-UPF3b (labeled #) and HA-SBP-eRF3b can pull down UPF2. Increasing amounts of SBP-UPF3b
(labeled *) pre-incubated with SBP-UPF2, reduce the amount of SBP-UPF2 binding to HA-SBP-eRF3b. BSA in the input material is indicated. IgG light
chain (LC) and molecular weight markers (kDa) are indicated. Experiments were analyzed by SDS-PAGE and Oriole Fluorescent Gel Stain (Bio-Rad)
staining.
(Figure 5C, SBP-UPF3b labeled *, precipitated SBP-UPF2
indicated within a square). This indicated a stronger inter-
action between UPF2 and UPF3b than between UPF2 and
eRF3. Taken together these results suggest that binding of
UPF2 to UPF3b interferes with the binding of UPF2 to
eRF3.
UPF2 associates with SURF in an UPF3-independent man-
ner
According to a prevailingmodel for NMD initiation, UPF2
is recruited on post-spliced mRNAs as part of an UPF2–
UPF3–EJC complex and the transient interaction of this
UPF2–UPF3–EJC complex with SURF at the ribosome
would stimulate SMG1-mediated UPF1 phosphorylation
(1,2). However, our finding that UPF2 forms a direct com-
plex with eRF3 provides an alternative pathway to recruit
UPF2 on the ribosome. This would agree with recent evi-
dence showing that UPF2 binds SURF components SMG1
and UPF1 in an UPF3-independent manner (10,28,31,33).
To test this possibility, we analyzed if UPF2 could be di-
rectly recruited to SURF and the ribosome in cells. HA-
tagged UPF2 (HA-UPF2) was expressed in HeLa TetOff
cells and the associated proteins analyzed after immunopre-
cipitation using an RNAase A treatment to discard RNA-
mediated interactions. We followed the input and precipi-
tated material by Western blot (WB) using antibodies for
markers of the SURF complex (SMG1 andUPF1), compo-
nents of the UPF3–EJC complex (UPF3,MLN51, eIF4A3,
Y14 and Magoh) and markers for the ribosome (ribosomal
proteins rpS6 and spL7a). We found that in these cells wt
UPF2 associated with the SURF complex, UPF3b and EJC
components, aswell as with ribosomal proteins (Figure 6A).
The association ofUPF2with all these proteins could repre-
sent the assembly of DECID and the interaction of UPF3-
EJC and SURF through UPF2 (2,9,10). Thus, it was im-
portant to test if UPF2 could be also recruited to SURF
and ribosomes if it is not part of a complex with UPF3b
and the EJC. When using UPF2-dU3 (in which residues
711–928 have been deleted) and UPF2-E858R, two UPF2
mutants with a reduced ability to bind UPF3b (10,49),
the expected reduction in precipitation of UPF3b and the
EJC was detected. Nevertheless, these mutants maintained
a similar binding to SURF and ribosomal components than
the wt protein (Figure 6A). In addition, we found that af-
ter polysome fractionation, UPF2 co-migrated with 80S ri-
bosome in absence of EDTA, which disrupt 80S ribosome,
(Figure 6B, left panel), or both 40S and 60S ribosomes in the
presence of EDTA that disrupts 80S ribosome (Figure 6B,
right panel), respectively. Together, these results indicated
that UPF2 could associate to SURF and ribosome compo-
nents in cells, in an UPF3–EJC-independent manner.
We further examined if UPF2 is part of the UPF3–EJC
complex in post-spliced mRNAs by determining the asso-
ciation between Flag-UPF2 and EJC/mRNA in an in vitro
splicing reaction coupled to immunoprecipitation analyses
usingHEK293T cell extracts (Figure 6C andD). UPF3, but
not UPF1 and UPF2, preferentially associated with spliced
mRNA after in vitro splicing, suggesting UPF2 might not
necessarily be a constituent component of a putativeUPF2–
UPF3–EJC complex after splicing.
DISCUSSION
The activation of mRNA degradation by the NMD path-
way is regulated by macromolecular interactions between
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Figure 6. UPF2 is recruited to SURF in an UPF3-independent manner. (A) Proteins associating to UPF2 in vivo. HA-tagged UPF2 as well as the UPF2-
dU3 and UPF2-E858R mutants affected in UPF3b binding were immunoprecipitated, and the associated proteins analyzed by western blot with the
indicated antibodies. UPF2 associates to SMG1, UPF1, UPF3, ribosomal proteins (rpS6, rpL7a) and EJC components (MLN51, eIF4A3, Y14, Magoh).
(B) Co-fractionation of UPF2 with ribosome. Cells were lysed in absence (left panel) or presence (right panel) of EDTA. 40S, 60S, 80S and polysomes
were separated according to size in a 8–45% sucrose gradient. UV profile for detection of 40S, 60S, 80S and polysome are shown on top. Fractions were
analyzed by western blot with the indicated antibodies (bottom panel). (C) Immunoprecipitation assay was carried out from an in vitro splicing reaction
with 32P-labeled Ade2 pre-mRNA (left panel) or with -crystallin pre-mRNA (right panel). For in vitro splicing, HeLa cell nuclear extracts were added to
the whole cell extracts fromHEK293T cells that had been transfected with control plasmid (Flag-vector), Flag-UPF1, UPF2 orUPF3b. RNAs precipitated
by anti-Flag antibody (IP lanes) were analyzed by SDS-PAGE. Schematic representations of pre-mRNAs and mRNAs are shown on the right of the panel.
Input lanes contain 5% of the total input material. (D) Analysis of the extracts from the cells transfected with control plasmid (Flag-vector), Flag-UPF1,
UPF2 or UPF3b was performed by western blot with the indicated antibodies. Molecular Weight markers are indicated (kDa).
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several protein factors, which are still not fully understood
(2). In mammals, UPF2 is able to form a direct complex
with several NMD factors, including UPF1, UPF3b and
SMG1. Here we incorporate eRF3 as an additional UPF2-
interacting factor by showing that human UPF2 and eRF3
can assemble a stable complex. Our study of the UPF2–
eRF3 complex using EM, together with the biochemical
analysis of the interaction of several fragments andmutants
of UPF2 with eRF3, reveals that UPF2 forms an open ring,
being mostly one side of UPF2 involved in the recognition
of eRF3. MIF4G-3 in UPF2 interacts with the N-terminal
RRM domain in UPF3b (32) and our structure suggests
that at least some parts of this region could be also in-
volved in eRF3 binding. Accordingly, truncation of residues
1016–1107 inUPF2 significantly reduce the interactionwith
eRF3, and the recombinant fragments of UPF2 compris-
ing MIF4G-3 domain, UPF2761-1054 and UPF2761-1227, in-
teract with eRF3 in interactions assays. This agrees with a
potential binding site for eRF3p in Upf2p described in Sac-
charomyces cerevisiae (37). MIF4G domains participate as
modules for the interaction with proteins in other contexts,
such as the Not1-Not2-Not5 module of the yeast Ccr4–Not
complex (50), and therefore it is conceivable that MIF4G
domains in UPF2 can bind several partners. Our finding
of a complex between UPF2 and eRF3 adds interesting in-
sights to our understanding of the complexity of NMD reg-
ulation, mainly on (a) how UPF2 is recruited to the target
mRNA and its mechanistic implications, and (b) the role of
UPF2 as a platform for different complexes.
How the NMD factors are recruited to mRNAs contain-
ing PTCs is not completely understood. UPF1 would be
recruited to stalled ribosomes through its interaction with
the eukaryotic release factors eRF1 and eRF3 as part of the
SURF complex (3,10). In addition,UPF1 can bindmRNAs
but translation affects its distribution on the mRNAs (11–
13). Inmammals, UPF2 is presumed to bind theUPF3-EJC
complex, but we show now that UPF2 binds also to eRF3
in vitro, and it associates with SURF and ribosomes in an
UPF3 and EJC-independent manner in cells. In addition,
unlike UPF3, UPF2 does not show preferential association
for spliced mRNA after in vitro splicing. Therefore, UPF2
can be recruited to SURF through direct interaction with
SMG1 (28,31), UPF1 (10) and eRF3, three of the four com-
ponents of SURF.
A direct recruitment of UPF2 to SURF can have impli-
cations in our understanding of how NMD initiation takes
place. An emerging view is that multiple pathways can con-
verge in the activation of an NMD response with distinct
requirements depending on organism, cell and transcript
(51–53). Some NMD events in mammals are independent
of a downstream EJC (34,35) and UPF3b (36). We show
evidence that UPF2 can form a complex with SURF and
ribosomal proteins independently of an EJC and UPF3.
This could be interpreted as a model where UPF2 can be
recruited to SURF first, rather than to UPF3–EJC, in addi-
tion to the previously proposed model implying formation
of the UPF2–UPF3–EJC complex (1–3,23). This model
might adapt to the faux 3′-UTR induced NMD, which is
EJC independent and conserved among eukaryote includ-
ing yeast, nematode and fly (2,35,53). Consistently, yeast
Upf2p can be recruited to 80S ribosome in an UPF3 inde-
pendent manner (54).
Our results also highlight the role of UPF2 as a platform
for protein interactions. UPF2 can bind many of the fac-
tors involved in the initial stages of the NMD response,
such as UPF1, UPF3, SMG1 and eRF3p, but we show
that not all of these can probably bind to UPF2 simulta-
neously. The regions of UPF2 involved in binding to eRF3
and UPF3b partially overlapped in the EM structure and
binding of UPF2 to UPF3b affects binding to eRF3. Con-
sistent with our results, yeast Upf3p and Upf2p competi-
tively binds eRF3 in vitro (37). This is particularly interest-
ing since eRF3 is bound to the stalled ribosome, whereas
UPF3b is thought to bind to the EJC. UPF3b could eventu-
ally displace eRF3 from an UPF2–eRF3 complex, because
UPF2 binds UPF3b with higher affinity than eRF3. The
interaction of UPF2 with eRF3 or UPF3, when previously
bound to the other partner, would probably require the dis-
placement of the other protein. At this stage, the differences
in affinities could be important. Similar findings have been
found for instance in splicing factor CWC22 (Complexed
With Cef1). CWC22 forms a complex with eIF4A3, which
is incompatible with the binding of eIF4A3 to MAGO and
Y14, two components of the EJC. Still CWC22 is required
to escort eIF4A3 to spliceosomes and promote binding to
MAGO and Y14 to assemble the EJC (55). It is worth men-
tioning that we have also found that eRF3 interacts with
UPF3b and the RRMmotif of UPF3b (Table 1). The bind-
ing of yeast eRF3p and Upf3p was also detected in vitro
(37). Therefore, even if there is a clash between UPF3b and
eRF3 when binding to UPF2, we cannot rule out that a tri-
partite complex containing UPF2, eRF3 and UPF3b could
be formed if eRF3 and UPF3b can still interact when one
of them is bound to UPF2. Consistent with this view, the
DECID complex assembled during NMD has been shown
to contain ribosome, the SURF complex, UPF2, UPF3 and
EJC (9,41).
Initiation of the NMD response requires the concerted
action of several factors. Here we describe an, up to our
knowledge, previously uncharacterized interaction between
human UPF2, one of these NMD factors and eRF3, to-
gether with evidence showing that UPF2 can be recruited
directly to the SURF complex and a stalled ribosome. These
interactions indicate that UPF2 possibly transits through
several complexes and organizes events regulating the ini-
tiation of the NMD response. The direct recruitment of
UPF2 to SURF and ribosomes could contribute to some
EJC and/or UPF3-independent NMD events described in
mammals.
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